Oskar Hansson

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1661466/publications.pdf

Version: 2024-02-01

		1701	4012
514	41,861	104	176
papers	citations	h-index	g-index

564	564	564	29734
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurology, The, 2006, 5, 228-234.	4.9	1,494
2	CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment. JAMA - Journal of the American Medical Association, 2009, 302, 385.	3.8	1,009
3	Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurology, The, 2020, 19, 422-433.	4.9	668
4	Plasma P-tau181 in Alzheimerâ€™s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimerâ€™s dementia. Nature Medicine, 2020, 26, 379-386.	15.2	643
5	Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA - Journal of the American Medical Association, 2020, 324, 772.	3.8	640
6	Earliest accumulation of Î²-amyloid occurs within the default-mode network and concurrently affects brain connectivity. Nature Communications, 2017, 8, 1214.	5.8	596
7	Cerebrospinal Fluid Levels ofÎ²-Amyloid 1-42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer Dementia. Archives of General Psychiatry, 2012, 69, 98.	13.8	554
8	Increased Sensitivity to N-Methyl-D-Aspartate Receptor-Mediated Excitotoxicity in a Mouse Model of Huntington's Disease. Neuron, 2002, 33, 849-860.	3.8	553
9	CSF biomarkers of Alzheimer's disease concord with amyloidâ€Î² PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimer's and Dementia, 2018, 14, 1470-1481.	0.4	468
10	Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. Lancet Neurology, The, 2017, 16, 661-676.	4.9	464
11	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. JAMA Neurology, 2019, 76, 1035.	4.5	455
12	Plasma Î²-amyloid in Alzheimerâ€™s disease and vascular disease. Scientific Reports, 2016, 6, 26801.	1.6	442
13	Interleukin-6 Is Elevated in the Cerebrospinal Fluid of Suicide Attempters and Related to Symptom Severity. Biological Psychiatry, 2009, 66, 287-292.	0.7	436
14	Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly People. Archives of Neurology, 2010, 67, 949.	4.9	407
15	Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and/or Parkinsonian Disorders. Archives of Neurology, 2012, 69, 1445.	4.9	407
16	Global genomic and transcriptomic analysis of human pancreatic islets reveals novel genes influencing glucose metabolism. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 13924-13929.	3.3	407
17	Amyloid biomarkers in Alzheimer's disease. Trends in Pharmacological Sciences, 2015, 36, 297-309.	4.0	404
18	Biomarkers for neurodegenerative diseases. Nature Medicine, 2021, 27, 954-963.	15.2	399

#	Article	IF	Citations
19	CSF and blood biomarkers for Parkinson's disease. Lancet Neurology, The, 2019, 18, 573-586.	4.9	393
20	Plasma tau in Alzheimer disease. Neurology, 2016, 87, 1827-1835.	1.5	371
21	Blood-based NfL. Neurology, 2017, 88, 930-937.	1.5	369
22	Blood-based biomarkers for Alzheimer's disease: towards clinical implementation. Lancet Neurology, The, 2022, 21, 66-77.	4.9	360
23	Four distinct trajectories of tau deposition identified in Alzheimerâ€™s disease. Nature Medicine, 2021, 27, 871-881.	15.2	354
24	Impact of an Exercise Intervention on DNA Methylation in Skeletal Muscle From First-Degree Relatives of Patients With Type 2 Diabetes. Diabetes, 2012, 61, 3322-3332.	0.3	334
25	<scp>CSF</scp> AÎ²42/AÎ²40 and AÎ²42/AÎ²38 ratios: better diagnostic markers of Alzheimer disease. Annals of Clinical and Translational Neurology, 2016, 3, 154-165.	1.7	329
26	Plasma tau levels in Alzheimer's disease. Alzheimer's Research and Therapy, 2013, 5, 9.	3.0	328
27	Improving the Survival of Grafted Dopaminergic Neurons: A Review over Current Approaches. Cell Transplantation, 2000, 9, 179-195.	1.2	327
28	Advantages and disadvantages of the use of the CSF Amyloid Î² (AÎ²) 42/40 ratio in the diagnosis of Alzheimerâ€™s Disease. Alzheimer's Research and Therapy, 2019, 11, 34.	3.0	325
29	Accuracy of Brain Amyloid Detection in Clinical Practice Using Cerebrospinal Fluid Î²-Amyloid 42. JAMA Neurology, 2014, 71, 1282.	4.5	300
30	Discriminative Accuracy of [¹⁸F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA - Journal of the American Medical Association, 2018, 320, 1151.	3.8	298
31	Cerebrospinal fluid analysis detects cerebral amyloid-Î² accumulation earlier than positron emission tomography. Brain, 2016, 139, 1226-1236.	3.7	292
32	Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. Neurology, 2015, 85, 1240-1249.	1.5	288
33	Spread of pathological tau proteins through communicating neurons in human Alzheimerâ€™s disease. Nature Communications, 2020, 11, 2612.	5.8	283
34	Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Diseaseâ€“Related Î²-Amyloid Status. JAMA Neurology, 2019, 76, 1060.	4.5	282
35	Caspase inhibition reduces apoptosis and increases survival of nigral transplants. Nature Medicine, 1999, 5, 97-100.	15.2	279
36	Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 1180-1190.	0.4	254

#	Article	IF	Citations
37	Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. Lancet Neurology, The, 2020, 19, 951-962.	4.9	254
38	Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimerâ€™s disease. Nature Communications, 2020, 11, 1683.	5.8	252
39	The cerebrospinal fluid â€œAlzheimer profileâ€: Easily said, but what does it mean?. Alzheimer's and Dementia, 2014, 10, 713.	0.4	249
40	Prediction of Alzheimerâ€™s Disease Using the CSF Aî²42/Aî²40 Ratio in Patients with Mild Cognitive Impairment. Dementia and Geriatric Cognitive Disorders, 2007, 23, 316-320.	0.7	248
41	Evaluation of plasma Aî²40 and Aî²42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiology of Aging, 2010, 31, 357-367.	1.5	242
42	Prediction of future Alzheimerâ€™s disease dementia using plasma phospho-tau combined with other accessible measures. Nature Medicine, 2021, 27, 1034-1042.	15.2	236
43	Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease. EMBO Molecular Medicine, 2019, 11, e11170.	3.3	228
44	Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurology, The, 2021, 20, 739-752.	4.9	220
45	Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease. EMBO Molecular Medicine, 2016, 8, 1184-1196.	3.3	219
46	A multicentre validation study of the diagnostic value of plasma neurofilament light. Nature Communications, 2021, 12, 3400.	5.8	219
47	SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimerâ€™s disease. Molecular Neurodegeneration, 2014, 9, 53.	4.4	216
48	Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 8727-8732.	3.3	215
49	Cerebrospinal fluid inflammatory markers in Parkinsonâ€™s disease â€“ Associations with depression, fatigue, and cognitive impairment. Brain, Behavior, and Immunity, 2013, 33, 183-189.	2.0	214
50	CCL2 Is Associated with a Faster Rate of Cognitive Decline during Early Stages of Alzheimer's Disease. PLoS ONE, 2012, 7, e30525.	1.1	209
51	CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. Neurology, 2018, 91, e867-e877.	1.5	207
52	Expression of TGF-î² isoforms, TGF-î² receptors, and SMAD molecules at different stages of human glioma. International Journal of Cancer, 2000, 89, 251-258.	2.3	206
53	Aî² deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimerâ€™s disease. Science Advances, 2020, 6, eaaz2387.	4.7	202
54	Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimerâ€™s Disease. journal of prevention of Alzheimer's disease, The, 2022, 9, 197-210.	1.5	201

#	Article	IF	Citations
55	Plasma GFAP is an early marker of amyloid-Î² but not tau pathology in Alzheimerâ€™s disease. Brain, 2021, 144, 3505-3516.	3.7	198
56	Mitochondrial Control of Acute Glutamate Excitotoxicity in Cultured Cerebellar Granule Cells. Journal of Neuroscience, 1998, 18, 10277-10286.	1.7	197
57	Associations between tau, AÎ², and cortical thickness with cognition in Alzheimer disease. Neurology, 2019, 92, e601-e612.	1.5	196
58	Î²-amyloid Peptides and Amyloid Plaques in Alzheimer's Disease. Neurotherapeutics, 2015, 12, 3-11.	2.1	195
59	Head-to-Head Comparison of 8 Plasma Amyloid-Î² 42/40 Assays in Alzheimer Disease. JAMA Neurology, 2021, 78, 1375.	4.5	195
60	Elevated Cerebrospinal Fluid BACE1 Activity in Incipient Alzheimer Disease. Archives of Neurology, 2008, 65, 1102-7.	4.9	193
61	Functional brain architecture is associated with the rate of tau accumulation in Alzheimerâ€™s disease. Nature Communications, 2020, 11, 347.	5.8	185
62	CSF biomarkers predict a more malignant outcome in Alzheimer disease. Neurology, 2010, 74, 1531-1537.	1.5	182
63	Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease. Brain Research, 2010, 1362, 13-22.	1.1	180
64	Non-Motor Symptoms in Patients with Parkinsonâ€™s Disease â€“ Correlations with Inflammatory Cytokines in Serum. PLoS ONE, 2012, 7, e47387.	1.1	180
65	Fluid biomarkers in Alzheimerâ€™s disease â€“ current concepts. Molecular Neurodegeneration, 2013, 8, 20.	4.4	180
66	Systematic development of small molecules to inhibit specific microscopic steps of AÎ²42 aggregation in Alzheimerâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E200-E208.	3.3	180
67	CSF biomarkers and clinical progression of Parkinson disease. Neurology, 2015, 84, 57-63.	1.5	178
68	Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease. JAMA Neurology, 2021, 78, 149.	4.5	176
69	The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, 1145-1156.	0.4	174
70	Levels of cerebrospinal fluid Î±-synuclein oligomers are increased in Parkinsonâ€™s disease with dementia and dementia with Lewy bodies compared to Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2014, 6, 25.	3.0	169
71	Medial temporal lobe connectivity and its associations with cognition in early Alzheimerâ€™s disease. Brain, 2020, 143, 1233-1248.	3.7	164
72	¹⁸Fâ€AVâ€1451 and CSF Tâ€tau and Pâ€tau as biomarkers in Alzheimer's disease. EMBO Molecular Medicine, 2017, 9, 1212-1223.	3.3	156

#	Article	IF	Citations
73	Age and diagnostic performance of Alzheimer disease CSF biomarkers. Neurology, 2012, 78, 468-476.	1.5	154
74	Increased blood-brain barrier permeability is associated with dementia and diabetes but not amyloid pathology or APOE genotype. Neurobiology of Aging, 2017, 51, 104-112.	1.5	154
75	Longitudinal plasma p-tau217 is increased in early stages of Alzheimerâ€™s disease. Brain, 2020, 143, 3234-3241.	3.7	150
76	¹⁸F-AV-1451 tau PET imaging correlates strongly with tau neuropathology inMAPTmutation carriers. Brain, 2016, 139, 2372-2379.	3.7	149
77	Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimerâ€™s disease. Brain, 2017, 140, 2286-2294.	3.7	149
78	Staging Î²-Amyloid Pathology With Amyloid Positron Emission Tomography. JAMA Neurology, 2019, 76, 1319.	4.5	149
79	Cerebrospinal Fluid Biomarkers Predict Decline in Subjective Cognitive Function over 3 Years in Healthy Elderly. Dementia and Geriatric Cognitive Disorders, 2007, 24, 118-124.	0.7	148
80	Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease. JAMA Neurology, 2021, 78, 961.	4.5	148
81	Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimerâ€™s disease. Acta Neuropathologica Communications, 2019, 7, 169.	2.4	146
82	Amyloid blood biomarker detects Alzheimer's disease. EMBO Molecular Medicine, 2018, 10, .	3.3	145
83	Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the huntington gene. European Journal of Neuroscience, 2001, 14, 1492-1504.	1.2	140
84	Prediagnostic body fat and risk of death from amyotrophic lateral sclerosis. Neurology, 2013, 80, 829-838.	1.5	138
85	Cerebrospinal fluid neurogranin and <scp>YKL</scp> â€40 as biomarkers of Alzheimer's disease. Annals of Clinical and Translational Neurology, 2016, 3, 12-20.	1.7	137
86	<scp>L</scp>ongitudinal <scp>M</scp>easurements of <scp>C</scp>erebrospinal <scp>F</scp>luid <scp>B</scp>iomarkers in <scp>P</scp>arkinson's <scp>D</scp>isease. Movement Disorders, 2016, 31, 898-905.	2.2	136
87	Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders. JAMA Neurology, 2020, 77, 955.	4.5	136
88	Association of Cerebral Amyloid-Î² Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84.	6.0	133
89	Prevalence of amyloidâ€Î² pathology in distinct variants of primary progressive aphasia. Annals of Neurology, 2018, 84, 729-740.	2.8	132
90	Novel Panel of Cerebrospinal Fluid Biomarkers for the Prediction of Progression to Alzheimer Dementia in Patients With Mild Cognitive Impairment. Archives of Neurology, 2007, 64, 366.	4.9	131

#	Article	IF	Citations
91	Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials. Lancet Neurology, The, 2022, 21, 726-734.	4.9	130
92	Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimerâ€™s disease. Acta Neuropathologica, 2019, 137, 279-296.	3.9	128
93	Low CSF Levels of Both Î±-Synuclein and the Î±-Synuclein Cleaving Enzyme Neurosin in Patients with Synucleinopathy. PLoS ONE, 2013, 8, e53250.	1.1	123
94	Predicting clinical decline and conversion to Alzheimerâ€™s disease or dementia using novel Elecsys AÎ²(1â€“42), pTau and tTau CSF immunoassays. Scientific Reports, 2019, 9, 19024.	1.6	123
95	Kinetic fingerprints differentiate the mechanisms of action of anti-AÎ² antibodies. Nature Structural and Molecular Biology, 2020, 27, 1125-1133.	3.6	123
96	Untangling the association of amyloid-Î² and tau with synaptic and axonal loss in Alzheimerâ€™s disease. Brain, 2021, 144, 310-324.	3.7	123
97	Bloodâ€based biomarkers for Alzheimer's disease. EMBO Molecular Medicine, 2022, 14, e14408.	3.3	122
98	The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2016, 8, 41.	3.0	121
99	Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimerâ€™s disease patients and controls. Acta Neuropathologica, 2014, 127, 633-643.	3.9	120
100	Evaluating Amyloid-Î² Oligomers in Cerebrospinal Fluid as a Biomarker for Alzheimerâ€™s Disease. PLoS ONE, 2013, 8, e66381.	1.1	119
101	Overexpression of heat shock protein 70 in R6/2 Huntingtonâ€™s disease mice has only modest effects on disease progression. Brain Research, 2003, 970, 47-57.	1.1	117
102	Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment. Alzheimer's Research and Therapy, 2021, 13, 68.	3.0	117
103	Genotyping and interpretation of STR-DNA: Low-template, mixtures and database matchesâ€”Twenty years of research and development. Forensic Science International: Genetics, 2015, 18, 100-117.	1.6	116
104	Heterozygous PINK1 p.G411S increases risk of Parkinsonâ€™s disease via a dominant-negative mechanism. Brain, 2017, 140, 98-117.	3.7	116
105	Plasma biomarkers of Alzheimerâ€™s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations. Nature Communications, 2021, 12, 3555.	5.8	115
106	<scp>I</scp>ncreased basal ganglia binding of ¹⁸<scp>FâAVâ1451</scp> in patients with progressive supranuclear palsy. Movement Disorders, 2017, 32, 108-114.	2.2	111
107	Evaluation of CSF Biomarkers as Predictors of Alzheimer's Disease: A Clinical Follow-Up Study of 4.7 Years. Journal of Alzheimer's Disease, 2010, 21, 1119-1128.	1.2	110
108	Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity. International Journal of Geriatric Psychiatry, 2010, 25, 403-410.	1.3	109

#	Article	IF	Citations
109	Alzheimerâ€™s disease cerebrospinal fluid biomarker in cognitively normal subjects. Brain, 2015, 138, 2701-2715.	3.7	109
110	Increased CSF biomarkers of angiogenesis in Parkinson disease. Neurology, 2015, 85, 1834-1842.	1.5	109
111	LifeTime and improving European healthcare through cell-based interceptive medicine. Nature, 2020, 587, 377-386.	13.7	108
112	Microglial Markers are Elevated in the Prodromal Phase of Alzheimer's Disease and Vascular Dementia. Journal of Alzheimer's Disease, 2012, 33, 45-53.	1.2	106
113	Evaluation of a Previously Suggested Plasma Biomarker Panel to Identify Alzheimer's Disease. PLoS ONE, 2012, 7, e29868.	1.1	106
114	Cerebrospinal fluid soluble TREM2 in aging and Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2016, 8, 17.	3.0	105
115	Cerebrospinal Fluid Microglial Markers in Alzheimerâ€™s Disease: Elevated Chitotriosidase Activity but Lack of Diagnostic Utility. NeuroMolecular Medicine, 2011, 13, 151-159.	1.8	104
116	Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimerâ€™s disease patients and healthy controls. Alzheimer's Research and Therapy, 2015, 7, 40.	3.0	104
117	Cerebrospinal fluid concentrations of inflammatory markers in Parkinsonâ€™s disease and atypical parkinsonian disorders. Scientific Reports, 2018, 8, 13276.	1.6	104
118	In vivo retention of ¹⁸ F-AV-1451 in corticobasal syndrome. Neurology, 2017, 89, 845-853.	1.5	103
119	Searching for the neurite density with diffusion MRI: Challenges for biophysical modeling. Human Brain Mapping, 2019, 40, 2529-2545.	1.9	103
120	Apathy and anxiety are early markers of Alzheimer's disease. Neurobiology of Aging, 2020, 85, 74-82.	1.5	103
121	Soluble TNF receptors are associated with AÎ² metabolism and conversion to dementia in subjects with mild cognitive impairment. Neurobiology of Aging, 2010, 31, 1877-1884.	1.5	101
122	Plasma amyloidâ€Îβ and risk of Alzheimer's disease in the Framingham Heart Study. Alzheimer's and Dementia, 2015, 11, 249.	0.4	101
123	Relationship between cortical iron and tau aggregation in Alzheimerâ€™s disease. Brain, 2020, 143, 1341-1349.	3.7	101
124	A Selected Reaction Monitoring (SRM)-Based Method for Absolute Quantification of AÎ²38, AÎ²40, and AÎ²42 in Cerebrospinal Fluid of Alzheimer's Disease Patients and Healthy Controls. Journal of Alzheimer's Disease, 2013, 33, 1021-1032.	1.2	100
125	Clinical validity of cerebrospinal fluid AÎ²42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiology of Aging, 2017, 52, 196-213.	1.5	100
126	Correlation of Longitudinal Cerebrospinal Fluid Biomarkers With Cognitive Decline in Healthy Older Adults. Archives of Neurology, 2010, 67, 217-23.	4.9	99

#	Article	IF	Citations
127	Low Incidence of Post-Lumbar Puncture Headache in 1,089 Consecutive Memory Clinic Patients. European Neurology, 2010, 63, 326-330.	0.6	99
128	Slowing of EEG correlates with CSF biomarkers and reduced cognitive speed in elderly with normal cognition over 4 years. Neurobiology of Aging, 2010, 31, 215-223.	1.5	97
129	Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment. JAMA Neurology, 2017, 74, 1492.	4.5	97
130	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology, 2022, 79, 228.	4.5	97
131	Determining clinically meaningful decline in preclinical Alzheimer disease. Neurology, 2019, 93, e322-e333.	1.5	96
132	AÎ²40 Oligomers Identified as a Potential Biomarker for the Diagnosis of Alzheimer's Disease. PLoS ONE, 2010, 5, e15725.	1.1	96
133	Amyloid-Î² Oligomers in Cerebrospinal Fluid are Associated with Cognitive Decline in Patients with Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 29, 171-176.	1.2	95
134	Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations. Nature Aging, 2021, 1, 114-123.	5.3	94
135	Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer's disease. Neurobiology of Aging, 2017, 58, 14-29.	1.5	93
136	Soluble Pâ€tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau. EMBO Molecular Medicine, 2021, 13, e14022.	3.3	90
137	Oxidative stress, mitochondrial permeability transition and activation of caspases in calcium ionophore A23187-induced death of cultured striatal neurons. Brain Research, 2000, 857, 20-29.	1.1	89
138	Molecular properties underlying regional vulnerability to Alzheimerâ€™s disease pathology. Brain, 2018, 141, 2755-2771.	3.7	89
139	Validation of Plasma Amyloid-Î² 42/40 for Detecting Alzheimer Disease Amyloid Plaques. Neurology, 2022, 98, .	1.5	89
140	Tau Pathology Distribution in Alzheimer's disease Corresponds Differentially to Cognition-Relevant Functional Brain Networks. Frontiers in Neuroscience, 2017, 11, 167.	1.4	87
141	The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review. Alzheimer's and Dementia, 2018, 14, 1313-1333.	0.4	87
142	Patient-centered connectivity-based prediction of tau pathology spread in Alzheimerâ€™s disease. Science Advances, 2020, 6, .	4.7	86
143	Patterns of Cell Death and Dopaminergic Neuron Survival in Intrastriatal Nigral Grafts. Experimental Neurology, 1999, 160, 279-288.	2.0	85
144	Apolipoprotein E Genotype and the Diagnostic Accuracy of Cerebrospinal Fluid Biomarkers for Alzheimer Disease. JAMA Psychiatry, 2014, 71, 1183.	6.0	85

#	Article	IF	Citations
145	Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. Lancet Neurology, The, 2019, 18, 1034-1044.	4.9	85
146	The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimerâ€™s but Not Parkinsonâ€™s Disease or Dementia with Lewy Bodies. PLoS ONE, 2015, 10, e0135458.	1.1	85
147	Altered striatal amino acid neurotransmitter release monitored using microdialysis in R6/1 Huntington transgenic mice. European Journal of Neuroscience, 2001, 13, 206-210.	1.2	84
148	An Integrated Workflow for Multiplex CSF Proteomics and Peptidomicsâ€”Identification of Candidate Cerebrospinal Fluid Biomarkers of Alzheimerâ€™s Disease. Journal of Proteome Research, 2015, 14, 654-663.	1.8	84
149	CSF/serum albumin ratio in dementias: a cross-sectional study on 1861 patients. Neurobiology of Aging, 2017, 59, 1-9.	1.5	84
150	Predicting diagnosis and cognition with ¹⁸Fâ€AVâ€1451 tau PET and structural MRI in Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 570-580.	0.4	84
151	Correlation of In Vivo [¹⁸F]Flortaucipir With Postmortem Alzheimer Disease Tau Pathology. JAMA Neurology, 2019, 76, 310.	4.5	84
152	Characterization of preâ€analytical sample handling effects on a panel of Alzheimer's diseaseâ€related bloodâ€based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group. Alzheimer's and Dementia, 2022, 18, 1484-1497.	0.4	84
153	Pleiotropic Effects of GIP on Islet Function Involve Osteopontin. Diabetes, 2011, 60, 2424-2433.	0.3	83
154	Comparing ¹⁸ F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease. Neurology, 2018, 90, e388-e395.	1.5	83
155	The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2140-2156.	3.3	83
156	Additive Effects of Caspase Inhibitor and Lazaroid on the Survival of Transplanted Rat and Human Embryonic Dopamine Neurons. Experimental Neurology, 2000, 164, 102-111.	2.0	80
157	The implications of different approaches to define AT(N) in Alzheimer disease. Neurology, 2020, 94, e2233-e2244.	1.5	80
158	Assessment of Demographic, Genetic, and Imaging Variables Associated With Brain Resilience and Cognitive Resilience to Pathological Tau in Patients With Alzheimer Disease. JAMA Neurology, 2020, 77, 632.	4.5	80
159	Distinct cerebrospinal fluid amyloid Î² peptide signatures in sporadic and PSEN1A431E-associated familial Alzheimer's disease. Molecular Neurodegeneration, 2010, 5, 2.	4.4	79
160	Longitudinal Study of CSF Biomarkers in Patients with Alzheimer's Disease. PLoS ONE, 2009, 4, e6294.	1.1	79
161	Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer's disease. Alzheimer's Research and Therapy, 2010, 2, 20.	3.0	78
162	Reference measurement procedure for <scp>CSF</scp> amyloid beta (AÎ²)_{1â€“42} and the <scp>CSF</scp> AÎ²_{1â€“42}/AÎ²_{1â€“40} ratio â€“ a crossâ€validation study against amyloid <scp>PET</scp>. Journal of Neurochemistry, 2016, 139, 651-658.	2.1	78

#	Article	IF	Citations
163	Mild behavioral impairment and its relation to tau pathology in preclinical Alzheimerâ€™s disease. Translational Psychiatry, 2021, 11, 76.	2.4	78
164	Early stages of tau pathology and its associations with functional connectivity, atrophy and memory. Brain, 2021, 144, 2771-2783.	3.7	78
165	Factors associated with fear of falling in people with Parkinsonâ€™s disease. BMC Neurology, 2014, 14, 19.	0.8	77
166	Increased midlife triglycerides predict brain Î²-amyloid and tau pathology 20 years later. Neurology, 2018, 90, e73-e81.	1.5	76
167	Link Between GIP and Osteopontin in Adipose Tissue and Insulin Resistance. Diabetes, 2013, 62, 2088-2094.	0.3	75
168	Extrapolation-Based References Improve Motion and Eddy-Current Correction of High B-Value DWI Data: Application in Parkinsonâ€™s Disease Dementia. PLoS ONE, 2015, 10, e0141825.	1.1	75
169	Discriminatory Analysis of Biochip-Derived Protein Patterns in CSF and Plasma in Neurodegenerative Diseases. Frontiers in Aging Neuroscience, 2011, 3, 1.	1.7	73
170	Comparison of Brief Cognitive Tests and CSF Biomarkers in Predicting Alzheimerâ€™s Disease in Mild Cognitive Impairment: Six-Year Follow-Up Study. PLoS ONE, 2012, 7, e38639.	1.1	73
171	Distinct tau PET patterns in atrophyâ€defined subtypes of Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, 335-344.	0.4	73
172	Practical suggestions on how to differentiate dementia with Lewy bodies from Alzheimer's disease with common cognitive tests. International Journal of Geriatric Psychiatry, 2009, 24, 1405-1412.	1.3	72
173	Tau oligomers in cerebrospinal fluid in Alzheimer's disease. Annals of Clinical and Translational Neurology, 2017, 4, 226-235.	1.7	72
174	Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma AÎ²42/AÎ²40 and pâ€tau. Alzheimer's and Dementia, 2022, 18, 283-293.	0.4	72
175	Exploring causality of the association between smoking and Parkinsonâ€™s disease. International Journal of Epidemiology, 2019, 48, 912-925.	0.9	70
176	Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease. Neurobiology of Aging, 2009, 30, 165-173.	1.5	69
177	Higher Cathepsin B Levels in Plasma in Alzheimer's Disease Compared to Healthy Controls. Journal of Alzheimer's Disease, 2011, 22, 1223-1230.	1.2	68
178	Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Diagnostic Performance in a Homogeneous Mono-Center Population. Journal of Alzheimer's Disease, 2011, 24, 537-546.	1.2	68
179	Cerebrospinal fluid tau fragment correlates with tau PET: a candidate biomarker for tangle pathology. Brain, 2020, 143, 650-660.	3.7	68
180	Cerebrospinal fluid levels of complement proteins C3, C4 and CR1 in Alzheimerâ€™s disease. Journal of Neural Transmission, 2012, 119, 789-797.	1.4	67

#	Article	IF	Citations
181	Towards unconstrained compartment modeling in white matter using diffusionâ€relaxation MRI with tensorâ€valued diffusion encoding. Magnetic Resonance in Medicine, 2020, 84, 1605-1623.	1.9	67
182	Cerebrospinal fluid lipocalin 2 as a novel biomarker for the differential diagnosis of vascular dementia. Nature Communications, 2020, 11, 619.	5.8	67
183	Serum but not cerebrospinal fluid levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) are increased in Alzheimer's disease. Psychoneuroendocrinology, 2013, 38, 1729-1737.	1.3	66
184	Myo-inositol changes precede amyloid pathology and relate to APOE genotype in Alzheimer disease. Neurology, 2016, 86, 1754-1761.	1.5	66
185	Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease. JAMA Neurology, 2022, 79, 149.	4.5	66
186	Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects. Brain, 2021, 144, 2826-2836.	3.7	65
187	The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects. Brain, 2020, 143, 3805-3815.	3.7	65
188	Extensive changes in the transcriptional profile of human adipose tissue including genes involved in oxidative phosphorylation after a 6â€month exercise intervention. Acta Physiologica, 2014, 211, 188-200.	1.8	62
189	Low <scp>IL</scp>â€8 is associated with anxiety in suicidal patients: genetic variation and decreased protein levels. Acta Psychiatrica Scandinavica, 2015, 131, 269-278.	2.2	62
190	Time to Amyloid Positivity and Preclinical Changes in Brain Metabolism, Atrophy, and Cognition: Evidence for Emerging Amyloid Pathology in Alzheimer's Disease. Frontiers in Neuroscience, 2017, 11, 281.	1.4	62
191	Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy. Acta Neuropathologica, 2017, 133, 149-151.	3.9	61
192	Head-to-head comparison of tau positron emission tomography tracers [18F]flortaucipir and [18F]RO948. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 342-354.	3.3	61
193	Assessment of Peptide Chemical Modifications on the Development of an Accurate and Precise Multiplex Selected Reaction Monitoring Assay for Apolipoprotein E Isoforms. Journal of Proteome Research, 2014, 13, 1077-1087.	1.8	60
194	Optimized Standard Operating Procedures for the Analysis of Cerebrospinal Fluid Aî²42 and the Ratios of Aî² Isoforms Using Low Protein Binding Tubes. Journal of Alzheimer's Disease, 2016, 53, 1121-1132.	1.2	60
195	ElecsysÂ® Total-Tau and Phospho-Tau (181P) CSF assays: Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid. Clinical Biochemistry, 2019, 72, 30-38.	0.8	60
196	Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays. Neurology, 2021, 97, e1681-e1694.	1.5	60
197	18F-AV-1451 in Parkinsonâ€™s Disease with and without dementia and in Dementia with Lewy Bodies. Scientific Reports, 2018, 8, 4717.	1.6	59
198	Electroencephalogram Variability in Dementia with Lewy Bodies, Alzheimerâ€™s Disease and Controls. Dementia and Geriatric Cognitive Disorders, 2008, 26, 284-290.	0.7	58

#	Article	IF	Citations
199	Prevalence of the apolipoprotein E Îµ4 allele in amyloid Î² positive subjects across the spectrum of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 913-924.	0.4	58
200	Tau PET correlates with different Alzheimerâ€™s diseaseâ€related features compared to CSF and plasma pâ€tau biomarkers. EMBO Molecular Medicine, 2021, 13, e14398.	3.3	58
201	Prediction of Falls and/or Near Falls in People with Mild Parkinsonâ€™s Disease. PLoS ONE, 2015, 10, e0117018.	1.1	57
202	Amyloid and tau accumulate across distinct spatial networks and are differentially associated with brain connectivity. ELife, 2019, 8, .	2.8	57
203	Greater tau load and reduced cortical thickness in APOE Îµ4-negative Alzheimerâ€™s disease: a cohort study. Alzheimer's Research and Therapy, 2018, 10, 77.	3.0	56
204	Association of Enlarged Perivascular Spaces and Measures of Small Vessel and Alzheimer Disease. Neurology, 2021, 96, e193-e202.	1.5	54
205	Current advances in plasma and cerebrospinal fluid biomarkers in Alzheimer's disease. Current Opinion in Neurology, 2021, 34, 266-274.	1.8	54
206	Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length. Journal of Neurochemistry, 2001, 78, 694-703.	2.1	53
207	Altered chemokine levels in the cerebrospinal fluid and plasma of suicide attempters. Psychoneuroendocrinology, 2013, 38, 853-862.	1.3	53
208	Modeling Strategies for Quantification of In Vivo ¹⁸F-AV-1451 Binding in Patients with Tau Pathology. Journal of Nuclear Medicine, 2017, 58, 623-631.	2.8	53
209	A Case of XXXXY Sex Chromosome Anomaly with Autoradiographic Studies. Cytogenetic and Genome Research, 1963, 2, 208-231.	0.6	52
210	Evolution of AÎ²42 and AÎ²40 levels and AÎ²42/AÎ²40 ratio in plasma during progression of Alzheimer's disease: A multicenter assessment. Journal of Nutrition, Health and Aging, 2009, 13, 205-208.	1.5	52
211	Body mass index is associated with biological CSF markers of core brain pathology of Alzheimer's disease. Neurobiology of Aging, 2012, 33, 1599-1608.	1.5	52
212	Cerebral white matter lesions â€“ associations with AÎ² isoforms and amyloid PET. Scientific Reports, 2016, 6, 20709.	1.6	52
213	Trace DNA collectionâ€”Performance of minitape and three different swabs. Forensic Science International: Genetics Supplement Series, 2009, 2, 189-190.	0.1	51
214	Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimerâ€™s and Parkinsonâ€™s disease. Alzheimer's Research and Therapy, 2019, 11, 82.	3.0	51
215	The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid Î² and tau. Alzheimer's and Dementia, 2021, 17, 1575-1582.	0.4	51
216	Identification of SPARC-like 1 Protein as Part of a Biomarker Panel for Alzheimer's Disease in Cerebrospinal Fluid. Journal of Alzheimer's Disease, 2012, 28, 625-636.	1.2	50

#	Article	IF	Citations
217	NG2 cells, a new trail for Alzheimerâ€™s disease mechanisms?. Acta Neuropathologica Communications, 2013, 1, 7.	2.4	50
218	MRI of the Swallow Tail Sign: A Useful Marker in the Diagnosis of Lewy Body Dementia?. American Journal of Neuroradiology, 2017, 38, 1737-1741.	1.2	50
219	Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimerâ€™s disease. BMC Neurology, 2020, 20, 10.	0.8	50
220	Assessing risk for preclinical Î²â€amyloid pathology with APOE, cognitive, and demographic information. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 4, 76-84.	1.2	49
221	Engineered antibodies: new possibilities for brain PET?. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2848-2858.	3.3	49
222	Accurate risk estimation of Î²â€amyloid positivity to identify prodromal Alzheimer's disease: Crossâ€validation study of practical algorithms. Alzheimer's and Dementia, 2019, 15, 194-204.	0.4	49
223	Longitudinal degeneration of the basal forebrain predicts subsequent dementia in Parkinson's disease. Neurobiology of Disease, 2020, 139, 104831.	2.1	49
224	The accuracy and robustness of plasma biomarker models for amyloid PET positivity. Alzheimer's Research and Therapy, 2022, 14, 26.	3.0	49
225	Cerebrospinal Fluid Biomarkers in Autopsy-Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration. Neurology, 2022, 98, .	1.5	49
226	Evaluation of Plasma AÎ² as Predictor of Alzheimer's Disease in Older Individuals Without Dementia: A Population-Based Study. Journal of Alzheimer's Disease, 2012, 28, 231-238.	1.2	48
227	Increased amyloidogenic APP processing in APOE É›4-negative individuals with cerebral Î²-amyloidosis. Nature Communications, 2016, 7, 10918.	5.8	48
228	Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimerâ€™s disease: an observational study. BMC Neurology, 2014, 14, 64.	0.8	46
229	Autocatalytic amplification of Alzheimer-associated AÎ²42 peptide aggregation in human cerebrospinal fluid. Communications Biology, 2019, 2, 365.	2.0	46
230	Midlife Atherosclerosis and Development of Alzheimer or Vascular Dementia. Annals of Neurology, 2020, 87, 52-62.	2.8	46
231	The period of hypotension following orthostatic challenge is prolonged in dementia with Lewy bodies. International Journal of Geriatric Psychiatry, 2008, 23, 192-198.	1.3	45
232	Evaluation of the Cerebrospinal Fluid Amyloid-Î²₁₋₄₂/Amyloid-Î²₁₋₄₀ Ratio Measured by Alpha-LISA to Distinguish Alzheimer's Disease from Other Dementia Disorders. Dementia and Geriatric Cognitive Disorders, 2013, 36, 99-110.	0.7	45
233	Cerebrospinal Fluid (CSF) 25-Hydroxyvitamin D Concentration and CSF Acetylcholinesterase Activity Are Reduced in Patients with Alzheimer's Disease. PLoS ONE, 2013, 8, e81989.	1.1	45
234	A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimerâ€™s disease. Scientific Reports, 2017, 7, 13333.	1.6	45

#	Article	IF	Citations
235	Leukocyte Telomere Length (LTL) is reduced in stable mild cognitive impairment but low LTL is not associated with conversion to Alzheimer's Disease: A pilot study. Experimental Gerontology, 2012, 47, 179-182.	1.2	44
236	Soluble amyloid precursor protein Î± and Î² in CSF in Alzheimer's disease. Brain Research, 2013, 1513, 117-126.	1.1	43
237	The A4 study: Î²â€amyloid and cognition in 4432 cognitively unimpaired adults. Annals of Clinical and Translational Neurology, 2020, 7, 776-785.	1.7	43
238	2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimerâ€™s disease in the context of a structured 5-phase development framework. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2121-2139.	3.3	43
239	Expression of Phosphofructokinase in Skeletal Muscle Is Influenced by Genetic Variation and Associated With Insulin Sensitivity. Diabetes, 2014, 63, 1154-1165.	0.3	41
240	A multicenter comparison of [18F]flortaucipir, [18F]RO948, and [18F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2295-2305.	3.3	41
241	FK506 and Cyclosporin A Enhance the Survival of Cultured and Grafted Rat Embryonic Dopamine Neurons. Experimental Neurology, 2000, 164, 94-101.	2.0	40
242	Proinflammatory Cytokines Are Elevated in Serum of Patients with Multiple System Atrophy. PLoS ONE, 2013, 8, e62354.	1.1	40
243	Cortical thinning in patients with REM sleep behavior disorder is associated with clinical progression. Npj Parkinson's Disease, 2019, 5, 7.	2.5	40
244	Mice transgenic for exon 1 of the Huntington's disease gene display reduced striatal sensitivity to neurotoxicity induced by dopamine and 6-hydroxydopamine. European Journal of Neuroscience, 2001, 14, 1425-1435.	1.2	39
245	Striatal changes in Parkinson disease: An investigation of morphology, functional connectivity and their relationship to clinical symptoms. Psychiatry Research - Neuroimaging, 2018, 275, 5-13.	0.9	39
246	Association Between Earliest Amyloid Uptake and Functional Connectivity in Cognitively Unimpaired Elderly. Cerebral Cortex, 2019, 29, 2173-2182.	1.6	39
247	CSF Mg and Ca as diagnostic markers for dementia with Lewy bodies. Neurobiology of Aging, 2009, 30, 1265-1271.	1.5	38
248	Reduced cerebrospinal fluid level of thyroxine in patients with Alzheimer's disease. Psychoneuroendocrinology, 2013, 38, 1058-1066.	1.3	38
249	Towards a unified protocol for handling of CSF before Î²-amyloid measurements. Alzheimer's Research and Therapy, 2019, 11, 63.	3.0	38
250	Elevated plasma levels of soluble CD40 in incipient Alzheimer's disease. Neuroscience Letters, 2009, 450, 56-59.	1.0	37
251	Cerebrospinal Fluid Levels of Heart Fatty Acid Binding Protein are Elevated Prodromally in Alzheimer's Disease and Vascular Dementia. Journal of Alzheimer's Disease, 2013, 34, 673-679.	1.2	37
252	Disease-specific structural changes in thalamus and dentatorubrothalamic tract in progressive supranuclear palsy. Neuroradiology, 2015, 57, 1079-1091.	1.1	37

#	Article	IF	Citations
253	Chapter 10 Improving the survival of grafted embryonic dopamine neurons in rodent models of Parkinson's disease. Progress in Brain Research, 2000, 127, 203-231.	0.9	36
254	Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies. Nature Communications, 2020, 11, 6252.	5.8	36
255	No Diagnostic Value of Plasma Clusterin in Alzheimer's Disease. PLoS ONE, 2012, 7, e50237.	1.1	36
256	Cellular localization of p-tau217 in brain and its association with p-tau217 plasma levels. Acta Neuropathologica Communications, 2022, 10, 3.	2.4	36
257	Lack of neuroprotection by heat shock protein 70 overexpression in a mouse model of global cerebral ischemia. Experimental Brain Research, 2004, 154, 442-449.	0.7	35
258	Preclinical Amyloid-Î² and Axonal Degeneration Pathology in Delirium. Journal of Alzheimer's Disease, 2016, 55, 371-379.	1.2	35
259	Alterations of Diffusion Kurtosis and Neurite Density Measures in Deep Grey Matter and White Matter in Parkinsonâ€™s Disease. PLoS ONE, 2016, 11, e0157755.	1.1	35
260	Diagnostic Power of 24S-Hydroxycholesterol in Cerebrospinal Fluid: Candidate Marker of Brain Health. Journal of Alzheimer's Disease, 2013, 36, 739-747.	1.2	34
261	Quantification of total apolipoprotein E and its specific isoforms in cerebrospinal fluid and blood in Alzheimerâ€™s disease and other neurodegenerative diseases. EuPA Open Proteomics, 2015, 8, 137-143.	2.5	34
262	The clinical significance of 10-m walk test standardizations in Parkinsonâ€™s disease. Journal of Neurology, 2018, 265, 1829-1835.	1.8	34
263	Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimerâ€™s disease. Neurobiology of Aging, 2020, 95, 143-153.	1.5	34
264	Plasma Phosphoâ€Tau Identifies Alzheimer's Coâ€Pathology in Patients with Lewy Body Disease. Movement Disorders, 2021, 36, 767-771.	2.2	34
265	Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimerâ€™s disease in the context of a structured 5-phase biomarker development framework. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2097-2109.	3.3	34
266	Flunarizine improves the survival of grafted dopaminergic neurons. Neuroscience, 1999, 94, 17-20.	1.1	33
267	Can CSF biomarkers or preâ€treatment progression rate predict response to cholinesterase inhibitor treatment in Alzheimer's disease?. International Journal of Geriatric Psychiatry, 2009, 24, 638-647.	1.3	33
268	Increased Levels of Hyaluronic Acid in Cerebrospinal Fluid in Patients with Vascular Dementia. Journal of Alzheimer's Disease, 2014, 42, 1435-1441.	1.2	33
269	Cerebral Microbleeds and White Matter Hyperintensities in Cognitively Healthy Elderly: A Cross-Sectional Cohort Study Evaluating the Effect of Arterial Stiffness. Cerebrovascular Diseases Extra, 2015, 5, 41-51.	0.5	33
270	Î±-synucleinâ^'lipoprotein interactions and elevated ApoE level in cerebrospinal fluid from Parkinson's disease patients. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 15226-15235.	3.3	33

#	Article	IF	Citations
271	Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimerâ€™s disease in the context of a structured 5-phase development framework. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2110-2120.	3.3	33
272	Prediction of Alzheimerâ€™s Disease Using a Cerebrospinal Fluid Pattern of C-Terminally Truncated Î²-Amyloid Peptides. Neurodegenerative Diseases, 2008, 5, 268-276.	0.8	32
273	Cerebrospinal Fluid Total Tau Is Associated with Shorter Survival in Dementia with Lewy Bodies. Dementia and Geriatric Cognitive Disorders, 2009, 28, 314-319.	0.7	32
274	The effect of white matter hyperintensities on statistical analysis of diffusion tensor imaging in cognitively healthy elderly and prodromal Alzheimer's disease. PLoS ONE, 2017, 12, e0185239.	1.1	32
275	Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias. Neurology, 2020, 95, e3026-e3035.	1.5	31
276	Performance of Î±Synuclein RT-QuIC in relation to neuropathological staging of Lewy body disease. Acta Neuropathologica Communications, 2022, 10, .	2.4	31
277	CSF biomarkers for Alzheimerâ€™s pathology and the effect size of APOE É›4. Molecular Psychiatry, 2014, 19, 148-149.	4.1	30
278	Posterior Accumulation of Tau and Concordant Hypometabolism in an Early-Onset Alzheimerâ€™s Disease Patient with Presenilin-1 Mutation. Journal of Alzheimer's Disease, 2016, 51, 339-343.	1.2	30
279	Atrophy of the Posterior Subiculum Is Associated with Memory Impairment, Tau- and AÎ² Pathology in Non-demented Individuals. Frontiers in Aging Neuroscience, 2017, 9, 306.	1.7	30
280	Altered structural network organization in cognitively normal individuals with amyloid pathology. Neurobiology of Aging, 2018, 64, 15-24.	1.5	30
281	Midlife physical activity is associated with lower incidence of vascular dementia but not Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2019, 11, 87.	3.0	30
282	Method comparison study of the ElecsysÂ® Î²-Amyloid (1â€“42) CSF assay versus comparator assays and LC-MS/MS. Clinical Biochemistry, 2019, 72, 7-14.	0.8	30
283	Brain myoinositol as a potential marker of amyloid-related pathology. Neurology, 2019, 92, e395-e405.	1.5	30
284	A Quick Test of cognitive speed is sensitive in detecting early treatment response in alzheimer disease. Alzheimer's Research and Therapy, 2010, 2, 29.	3.0	29
285	Assessment of Global and Regional Diffusion Changes along White Matter Tracts in Parkinsonian Disorders by MR Tractography. PLoS ONE, 2013, 8, e66022.	1.1	29
286	Abnormal Structural Brain Connectome in Individuals with Preclinical Alzheimerâ€™s Disease. Cerebral Cortex, 2018, 28, 3638-3649.	1.6	29
287	Quantification of total apolipoprotein E and its isoforms in cerebrospinal fluid from patients with neurodegenerative diseases. Alzheimer's Research and Therapy, 2020, 12, 19.	3.0	29
288	A Genetic Variant of the Sortilin 1 Gene isÂAssociated with Reduced Risk ofÂAlzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 53, 1353-1363.	1.2	28

#	Article	IF	Citations
289	Cognitive and functional changes associated with AÎ² pathology and the progression to mild cognitive impairment. Neurobiology of Aging, 2016, 48, 172-181.	1.5	28
290	Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders. Proteomics - Clinical Applications, 2017, 11, 1700100.	0.8	28
291	Amyloid Network Topology Characterizes the Progression of Alzheimerâ€™s Disease During the Predementia Stages. Cerebral Cortex, 2018, 28, 340-349.	1.6	28
292	Î²-amyloid pathology and hippocampal atrophy are independently associated with memory function in cognitively healthy elderly. Scientific Reports, 2019, 9, 11180.	1.6	28
293	Association Between Apolipoprotein E Îµ2 vs Îµ4, Age, and Î²-Amyloid in Adults Without Cognitive Impairment. JAMA Neurology, 2021, 78, 229.	4.5	28
294	Accelerated inflammatory aging in Alzheimerâ€™s disease and its relation to amyloid, tau, and cognition. Scientific Reports, 2021, 11, 1965.	1.6	28
295	Spatial navigation measured by the Floor Maze Test in patients with subjective cognitive impairment, mild cognitive impairment, and mild Alzheimer's disease. International Psychogeriatrics, 2015, 27, 1401-1409.	0.6	27
296	Amyloid pathology in the progression to mild cognitive impairment. Neurobiology of Aging, 2018, 64, 76-84.	1.5	27
297	Dataâ€driven approaches for tauâ€PET imaging biomarkers in Alzheimer's disease. Human Brain Mapping, 2019, 40, 638-651.	1.9	27
298	Comparing progression biomarkers in clinical trials of early Alzheimerâ€™s disease. Annals of Clinical and Translational Neurology, 2020, 7, 1661-1673.	1.7	27
299	The impact of demographic, clinical, genetic, and imaging variables on tau PET status. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2245-2258.	3.3	27
300	Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9â€year study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 403-411.	1.2	26
301	Biomarkers of microvascular endothelial dysfunction predict incident dementia: a populationâ€based prospective study. Journal of Internal Medicine, 2017, 282, 94-101.	2.7	26
302	18F-Flortaucipir in TDP-43 associated frontotemporal dementia. Scientific Reports, 2019, 9, 6082.	1.6	26
303	Tau PET Imaging in Neurodegenerative Disorders. Journal of Nuclear Medicine, 2022, 63, 20S-26S.	2.8	26
304	Cystatin C Levels are Positively Correlated with both AÎ²42 and Tau Levels in Cerebrospinal Fluid in Persons with Alzheimer's Disease, Mild Cognitive Impairment, and Healthy Controls. Journal of Alzheimer's Disease, 2010, 21, 471-478.	1.2	25
305	Differences in Survival between Patients with Dementia with Lewy Bodies and Patients with Alzheimer's Disease - Measured from a Fixed Cognitive Level. Dementia and Geriatric Cognitive Disorders, 2011, 32, 408-416.	0.7	25
306	External validation of a 3-step falls prediction model in mild Parkinsonâ€™s disease. Journal of Neurology, 2016, 263, 2462-2469.	1.8	25

#	Article	IF	Citations
307	Characterization of degradation and heterozygote balance by simulation of the forensic DNA analysis process. International Journal of Legal Medicine, 2017, 131, 303-317.	1.2	25
308	Slowly progressive dementia caused by MAPT R406W mutations: longitudinal report on a new kindred and systematic review. Alzheimer's Research and Therapy, 2018, 10, 2.	3.0	25
309	Acute phase markers in CSF reveal inflammatory changes in Alzheimerâ€™s disease that intersect with pathology, APOE Îµ4, sex and age. Progress in Neurobiology, 2021, 198, 101904.	2.8	25
310	Plasma phosphorylated tau181 and neurodegeneration in Alzheimerâ€™s disease. Annals of Clinical and Translational Neurology, 2021, 8, 259-265.	1.7	25
311	Towards clinical application of tau PET tracers for diagnosing dementia due to Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, 1998-2008.	0.4	25
312	Prediction of Alzheimerâ€™s Disease Using Midregional Proadrenomedullin and Midregional Proatrial Natriuretic Peptide. Journal of Clinical Psychiatry, 2011, 72, 556-563.	1.1	25
313	Antihypertensive Therapy Is Associated with Reduced Rate of Conversion to Alzheimer's Disease in Midregional Proatrial Natriuretic Peptide Stratified Subjects with Mild Cognitive Impairment. Biological Psychiatry, 2011, 70, 145-151.	0.7	24
314	Characterisation of artefacts and drop-in events using STR-validator and single-cell analysis. Forensic Science International: Genetics, 2017, 30, 57-65.	1.6	24
315	Plasma <scp>NT1</scp> Tau is a Specific and Early Marker of Alzheimer's Disease. Annals of Neurology, 2020, 88, 878-892.	2.8	24
316	The BIN1 rs744373 Alzheimer's disease risk SNP is associated with faster AÎ²â€associated tau accumulation and cognitive decline. Alzheimer's and Dementia, 2022, 18, 103-115.	0.4	24
317	Cerebrospinal fluid neurofilament light chain differentiates primary psychiatric disorders from rapidly progressive, Alzheimer's disease and frontotemporal disorders in clinical settings. Alzheimer's and Dementia, 2022, 18, 2218-2233.	0.4	24
318	Testâ€retest variability of plasma biomarkers in Alzheimer's disease and its effects on clinical prediction models. Alzheimer's and Dementia, 2023, 19, 797-806.	0.4	24
319	Alteration of putaminal fractional anisotropy in Parkinsonâ€™s disease: a longitudinal diffusion kurtosis imaging study. Neuroradiology, 2018, 60, 247-254.	1.1	23
320	A fast analysis system for forensic DNA reference samples. Forensic Science International: Genetics, 2008, 2, 184-189.	1.6	22
321	Telomere length in blood and skeletal muscle in relation to measures of glycaemia and insulinaemia. Diabetic Medicine, 2012, 29, e377-81.	1.2	22
322	Correlations of CSF tau and amyloid levels with Alzheimer pathology in neuropathologically verified dementia with Lewy bodies. International Journal of Geriatric Psychiatry, 2013, 28, 738-744.	1.3	22
323	Preclinical effects of APOE Îµ4 on cerebrospinal fluid AÎ²42 concentrations. Alzheimer's Research and Therapy, 2017, 9, 87.	3.0	22
324	Cerebrospinal Fluid Levels of Neurogranin in Parkinsonian Disorders. Movement Disorders, 2020, 35, 513-518.	2.2	22

#	Article	IF	Citations
325	The strategic biomarker roadmap for the validation of Alzheimerâ€™s diagnostic biomarkers: methodological update. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2070-2085.	3.3	22
326	Association of Î²-Amyloid Accumulation With Executive Function in Adults With Unimpaired Cognition. Neurology, 2022, 98, .	1.5	22
327	First-Degree Relatives of Type 2 Diabetic Patients Have Reduced Expression of Genes Involved in Fatty Acid Metabolism in Skeletal Muscle. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E1332-E1337.	1.8	21
328	Cerebral hypoperfusion is not associated with an increase in amyloid Î² pathology in middleâ€aged or elderly people. Alzheimer's and Dementia, 2018, 14, 54-61.	0.4	21
329	Sex differences in off-target binding using tau positron emission tomography. NeuroImage: Clinical, 2021, 31, 102708.	1.4	21
330	Development of Apathy, Anxiety, and Depression in Cognitively Unimpaired Older Adults: Effects of Alzheimerâ€™s Disease Pathology and Cognitive Decline. Biological Psychiatry, 2022, 92, 34-43.	0.7	21
331	Grafting of Nigral Tissue Hibernated with Tirilazad Mesylate and Glial Cell Line-Derived Neurotrophic Factor. Cell Transplantation, 2000, 9, 577-584.	1.2	20
332	Cube Copying Test in Combination with rCBF or CSF AÎ²₄₂Predicts Development of Alzheimerâ€™s Disease. Dementia and Geriatric Cognitive Disorders, 2008, 25, 544-552.	0.7	20
333	Efficacy of memantine in PDD and DLB: an extension study including washout and open-label treatment. International Journal of Geriatric Psychiatry, 2011, 26, 206-213.	1.3	20
334	Tau Pathology and Parietal White Matter Lesions Have Independent but Synergistic Effects on Early Development of Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders Extra, 2013, 3, 113-122.	0.6	20
335	Cerebrospinal fluid levels of IL-6 are decreased and correlate with cognitive status in DLB patients. Alzheimer's Research and Therapy, 2015, 7, 63.	3.0	20
336	The interactive effect of demographic and clinical factors on hippocampal volume: A multicohort study on 1958 cognitively normal individuals. Hippocampus, 2017, 27, 653-667.	0.9	20
337	Diffusion Tensor MRI to Distinguish Progressive Supranuclear Palsy from Î±-Synucleinopathies. Radiology, 2019, 293, 646-653.	3.6	20
338	Increased functional connectivity of thalamic subdivisions in patients with Parkinsonâ€™s disease. PLoS ONE, 2019, 14, e0222002.	1.1	20
339	Time between milestone events in the Alzheimer's disease amyloid cascade. NeuroImage, 2021, 227, 117676.	2.1	20
340	Preâ€analytical protocol for measuring Alzheimer's disease biomarkers in fresh CSF. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12137.	1.2	20
341	Predicting Long-Term Cognitive Outcome with New Regression Models in Donepezil-Treated Alzheimer Patients in a Naturalistic Setting. Dementia and Geriatric Cognitive Disorders, 2008, 26, 203-211.	0.7	19
342	Converging Pathways of Chromogranin and Amyloid Metabolism in the Brain. Journal of Alzheimer's Disease, 2010, 20, 1039-1049.	1.2	19

#	Article	IF	Citations
343	Cerebrospinal Fluid Levels of sAPPÎ±and sAPPÎ²in Lewy Body and Alzheimer's Disease: Clinical and Neurochemical Correlates. International Journal of Alzheimer's Disease, 2011, 2011, 1-6.	1.1	19
344	Clinical value of cerebrospinal fluid neurofilament light chain in semantic dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 997-1004.	0.9	19
345	Beta-blocker therapy and risk of vascular dementia: A population-based prospective study. Vascular Pharmacology, 2020, 125-126, 106649.	1.0	19
346	No independent association between pulse wave velocity and dementia. Journal of Hypertension, 2017, 35, 2462-2467.	0.3	18
347	Mapping of apparent susceptibility yields promising diagnostic separation of progressive supranuclear palsy from other causes of parkinsonism. Scientific Reports, 2019, 9, 6079.	1.6	18
348	Diagnostic and prognostic performance to detect Alzheimerâ€™s disease and clinical progression of a novel assay for plasma p-tau217. Alzheimer's Research and Therapy, 2022, 14, 67.	3.0	18
349	Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, Î±-synuclein, and total tau in combination with AÎ²(1â€“42)/AÎ²(1â€“40). Alzheimer's Research and Therapy, 2017, 9, 40.	3.0	17
350	Assessment of kallikrein 6 as a cross-sectional and longitudinal biomarker for Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2018, 10, 9.	3.0	17
351	European Ultrahighâ€Field Imaging Network for Neurodegenerative Diseases (EUFIND). Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 538-549.	1.2	17
352	CDH6 and HAGH protein levels in plasma associate with Alzheimerâ€™s disease in APOE Îµ4 carriers. Scientific Reports, 2020, 10, 8233.	1.6	17
353	Alcohol Consumption and Risk of Parkinson's Disease: Data From a Large Prospective European Cohort. Movement Disorders, 2020, 35, 1258-1263.	2.2	17
354	Neuroligin-1 in brain and CSF of neurodegenerative disorders: investigation for synaptic biomarkers. Acta Neuropathologica Communications, 2021, 9, 19.	2.4	17
355	Heterogeneous distribution of tau pathology in the behavioural variant of Alzheimerâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 872-880.	0.9	17
356	The global Alzheimer's Association round robin study on plasma amyloid Î² methods. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12242.	1.2	17
357	Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimerâ€™s dementia in mild cognitive impairment patients. Alzheimer's Research and Therapy, 2022, 14, 46.	3.0	17
358	Detection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers. JAMA Neurology, 2022, 79, 797.	4.5	17
359	Low Levels of Soluble NG2 in Cerebrospinal Fluid from Patients with Dementia with Lewy Bodies. Journal of Alzheimer's Disease, 2014, 40, 343-350.	1.2	16
360	STR-validator: An open source platform for validation and process control. Forensic Science International: Genetics, 2014, 13, 154-166.	1.6	16

#	Article	IF	Citations
361	Parkinson's Disease Case Ascertainment in the EPIC Cohort: The NeuroEPIC4PD Study. Neurodegenerative Diseases, 2015, 15, 331-338.	0.8	16
362	Levels of islet amyloid polypeptide in cerebrospinal fluid and plasma from patients with Alzheimerâ€™s disease. PLoS ONE, 2019, 14, e0218561.	1.1	16
363	A new perspective for advanced positron emission tomographyâ€“based molecular imaging in neurodegenerative proteinopathies. Alzheimer's and Dementia, 2019, 15, 1081-1103.	0.4	16
364	Cerebrospinal fluid neurogranin in an inducible mouse model of neurodegeneration: A translatable marker of synaptic degeneration. Neurobiology of Disease, 2020, 134, 104645.	2.1	16
365	A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [18F]flutemetamol amyloid PET images. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2183-2199.	3.3	16
366	Association of CSF AÎ² ₃₈ Levels With Risk of Alzheimer Diseaseâ€“Related Decline. Neurology, 2022, 98, .	1.5	16
367	Effects of APOE Îµ4 on neuroimaging, cerebrospinal fluid biomarkers, and cognition in prodromal Alzheimer's disease. Neurobiology of Aging, 2018, 71, 81-90.	1.5	15
368	Image reconstruction methods affect software-aided assessment of pathologies of [18F]flutemetamol and [18F]FDG brain-PET examinations in patients with neurodegenerative diseases. NeuroImage: Clinical, 2020, 28, 102386.	1.4	15
369	CSF Biomarkers Correlate with Cerebral Blood Flow on SPECT in Healthy Elderly. Dementia and Geriatric Cognitive Disorders, 2012, 33, 156-163.	0.7	14
370	Cognitively normal women with Alzheimerâ€™s disease proteinopathy show relative preservation of memory but not of hippocampal volume. Alzheimer's Research and Therapy, 2019, 11, 109.	3.0	14
371	Parkinsonâ€™s disease: evolution of cognitive impairment and CSF AÎ²_{1â€“42} profiles in a prospective longitudinal study. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 165-170.	0.9	14
372	Derivation and utility of an AÎ²-PET pathology accumulation index to estimate AÎ² load. Neurology, 2020, 95, e2834-e2844.	1.5	14
373	The age-related effect on cognitive performance in cognitively healthy elderly is mainly caused by underlying AD pathology or cerebrovascular lesions: implications for cutoffs regarding cognitive impairment. Alzheimer's Research and Therapy, 2020, 12, 30.	3.0	14
374	Subtypes of Alzheimerâ€™s disease: questions, controversy, and meaning. Trends in Neurosciences, 2022, 45, 342-345.	4.2	14
375	A comparison of three automated DNA purification methods in Forensic casework. Forensic Science International: Genetics Supplement Series, 2008, 1, 76-77.	0.1	13
376	Monte Carlo feature selection and rule-based models to predict Alzheimerâ€™s disease in mild cognitive impairment. Journal of Neural Transmission, 2012, 119, 821-831.	1.4	13
377	AÎ²1-15/16 as a Potential Diagnostic Marker in Neurodegenerative Diseases. NeuroMolecular Medicine, 2013, 15, 169-179.	1.8	13
378	Less pronounced response to exercise in healthy relatives to type 2 diabetic subjects compared with controls. Journal of Applied Physiology, 2015, 119, 953-960.	1.2	13

#	Article	IF	Citations
379	Serum Neurofilament Light Chain as a Marker of Progression in Parkinsonâ€™s Disease: Long-Term Observation and Implications of Clinical Subtypes. Journal of Parkinson's Disease, 2022, 12, 571-584.	1.5	13
380	The protective gene dose effect of the APOEÎµ2 allele on gray matter volume in cognitively unimpaired individuals. Alzheimer's and Dementia, 2022, 18, 1383-1395.	0.4	13
381	Neuronal death in nigral grafts in the absence of poly (ADP-ribose) polymerase activation. NeuroReport, 1999, 10, 3347-3351.	0.6	12
382	Endogenous beta-cell CART regulates insulin secretion and transcription of beta-cell genes. Molecular and Cellular Endocrinology, 2017, 447, 52-60.	1.6	12
383	Dietary intervention with an Okinawan-based Nordic diet in type 2 diabetes renders decreased interleukin-18 concentrations and increased neurofilament light concentrations in plasma. Nutrition Research, 2018, 60, 13-25.	1.3	12
384	Low prevalence of known pathogenic mutations in dominant PD genes: A Swedish multicenter study. Parkinsonism and Related Disorders, 2019, 66, 158-165.	1.1	12
385	Cerebrospinal Fluid Concentrations of Extracellular Matrix Proteins in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2019, 69, 1213-1220.	1.2	12
386	Cerebrospinal fluid N-224 tau helps discriminate Alzheimerâ€™s disease from subjective cognitive decline and other dementias. Alzheimer's Research and Therapy, 2021, 13, 38.	3.0	12
387	The Usefulness of Cube Copying for Evaluating Treatment of Alzheimer's Disease. American Journal of Alzheimer's Disease and Other Dementias, 2008, 23, 439-446.	0.9	11
388	A quick test of cognitive speed can predict development of dementia in Parkinsonâ€™s disease. Scientific Reports, 2019, 9, 15417.	1.6	11
389	Differential expression of cerebrospinal fluid neuroinflammatory mediators depending on osteoarthritis pain phenotype. Pain, 2020, 161, 2142-2154.	2.0	11
390	Biomarker profiling beyond amyloid and tau: cerebrospinal fluid markers, hippocampal atrophy, and memory change in cognitively unimpaired older adults. Neurobiology of Aging, 2020, 93, 1-15.	1.5	11
391	Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimerâ€™s disease in the context of a structured 5-phase development framework. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2086-2096.	3.3	11
392	Structural and functional neuroimaging changes associated with cognitive impairment and dementia in Parkinson's disease. Psychiatry Research - Neuroimaging, 2021, 312, 111273.	0.9	11
393	Cyclosporin A and Bcl-2 do not inhibit quinolinic acid-induced striatal excitotoxicity in rodents. Experimental Neurology, 2003, 183, 430-437.	2.0	10
394	Mild dementia is associated with increased adrenal secretion of cortisol and precursor sex steroids in women. Clinical Endocrinology, 2011, 75, 301-308.	1.2	10
395	Clinical validity of CSF biomarkers for Alzheimer's disease: necessary indeed, but sufficient?. Lancet Neurology, The, 2016, 15, 650-651.	4.9	10
396	Alpha-amylase 1A copy number variants and the association with memory performance and Alzheimerâ€™s dementia. Alzheimer's Research and Therapy, 2020, 12, 158.	3.0	10

#	Article	IF	Citations
397	Medial temporal atrophy in preclinical dementia: Visual and automated assessment during six year follow-up. NeuroImage: Clinical, 2020, 27, 102310.	1.4	10
398	Tau-related grey matter network breakdown across the Alzheimerâ€™s disease continuum. Alzheimer's Research and Therapy, 2021, 13, 138.	3.0	10
399	Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2259-2271.	3.3	10
400	Plasma neurofilament light chain protein is not increased in treatment-resistant schizophrenia and first-degree relatives. Australian and New Zealand Journal of Psychiatry, 2022, 56, 1295-1305.	1.3	10
401	Flt3 ligand does not differentiate between Parkinsonian disorders. Movement Disorders, 2014, 29, 1319-1322.	2.2	9
402	The Swedish SCOPA-SLEEP for assessment of sleep disorders in Parkinsonâ€™s disease and healthy controls. Quality of Life Research, 2016, 25, 2571-2577.	1.5	9
403	Use of the tau protein-to-peptide ratio in CSF to improve diagnostic classification of Alzheimerâ€™s disease. Clinical Mass Spectrometry, 2019, 14, 74-82.	1.9	9
404	CSF placental growth factor â€“ a novel candidate biomarker of frontotemporal dementia. Annals of Clinical and Translational Neurology, 2019, 6, 863-872.	1.7	9
405	Application of advanced brain positron emission tomographyâ€“based molecular imaging for a biological framework in neurodegenerative proteinopathies. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 327-332.	1.2	9
406	Alzheimer Disease: Standard of Diagnosis, Treatment, Care, and Prevention. Journal of Nuclear Medicine, 2022, 63, 981-985.	2.8	9
407	Is longitudinal tau PET ready for use in Alzheimerâ€™s disease clinical trials?. Brain, 2018, 141, 1241-1244.	3.7	8
408	Maximizing Safety in the Conduct of Alzheimerâ€™s Disease Fluid Biomarker Research in the Era of COVID-19. Journal of Alzheimer's Disease, 2020, 76, 27-31.	1.2	8
409	The Effects of Tau, Amyloid, and White Matter Lesions on Mobility, Dual Tasking, and Balance in Older People. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2021, 76, 683-691.	1.7	8
410	Tau pathology mediates age effects on medial temporal lobe structure. Neurobiology of Aging, 2022, 109, 135-144.	1.5	8
411	Central nervous system monoaminergic activity in hip osteoarthritis patients with disabling pain: associations with pain severity and central sensitization. Pain Reports, 2022, 7, e988.	1.4	8
412	The Neuroinflammatory Acute Phase Response in Parkinsonianâ€Related Disorders. Movement Disorders, 2022, 37, 993-1003.	2.2	8
413	A porous silicon immunoassay platform for fluorometric determination of Î±-synuclein in human cerebrospinal fluid. Mikrochimica Acta, 2014, 181, 1143-1149.	2.5	7
414	Association of IL1RAP-related genetic variation with cerebrospinal fluid concentration of Alzheimer-associated tau protein. Scientific Reports, 2019, 9, 2460.	1.6	7

#	Article	IF	Citations
415	Components of gait in people with and without mild cognitive impairment. Gait and Posture, 2022, 93, 83-89.	0.6	7
416	Kinesin gene variability may affect tau phosphorylation in early Alzheimer's disease. International Journal of Molecular Medicine, 2007, 20, 233.	1.8	6
417	Hepatocyte growth factor in cerebrospinal fluid differentiates community-acquired or nosocomial septic meningitis from other causes of pleocytosis. Fluids and Barriers of the CNS, 2015, 12, 22.	2.4	6
418	Associations between TOMM40 Poly-T Repeat Variants and Dementia in Cases with Parkinsonism. Journal of Parkinson's Disease, 2016, 6, 99-108.	1.5	6
419	[18F]Flortaucipir distinguishes Alzheimerâ€™s disease from progressive supranuclear palsy pathology in a mixed-pathology case. Acta Neuropathologica, 2020, 139, 411-413.	3.9	6
420	Biomarker testing in MCI patientsâ€”deciding who to test. Alzheimer's Research and Therapy, 2021, 13, 14.	3.0	6
421	Genetic effects on longitudinal cognitive decline during the early stages of Alzheimerâ€™s disease. Scientific Reports, 2021, 11, 19853.	1.6	6
422	Detecting amyloid positivity in early Alzheimer disease using plasma biomarkers. Alzheimer's and Dementia, 2021, 17, .	0.4	6
423	Reply: Do we still need positron emission tomography for early Alzheimerâ€™s disease diagnosis?. Brain, 2016, 139, e61-e61.	3.7	5
424	Cerebrospinal fluid AÎ²42/AÎ²40 and AÎ²42/AÎ²38 as biomarkers of Alzheimerâ€™s disease. Neurobiology of Aging, 2016, 39, S28.	1.5	5
425	N-Terminal Prosomatostatin and Risk of Vascular Dementia. Cerebrovascular Diseases, 2017, 44, 259-265.	0.8	5
426	Psychometric testing of a Swedish version of the Apathy Evaluation Scale. Nordic Journal of Psychiatry, 2017, 71, 477-484.	0.7	5
427	Regional times to equilibria and their impact on semi-quantification of [18F]AV-1451 uptake. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 2223-2232.	2.4	5
428	Structural imaging findings on non-enhanced computed tomography are severely underreported in the primary care diagnostic work-up of subjective cognitive decline. Neuroradiology, 2019, 61, 397-404.	1.1	5
429	High circulating levels of midregional proenkephalin A predict vascular dementia: a population-based prospective study. Scientific Reports, 2020, 10, 8027.	1.6	5
430	Health utility in preclinical and prodromal Alzheimer's disease for establishing the value of new diseaseâ€modifying treatmentsâ€”EQâ€5D data from the Swedish BioFINDER study. Alzheimer's and Dementia, 2021, 17, 1832-1842.	0.4	5
431	Decreased pain sensitivity and alterations of cerebrospinal fluid and plasma inflammatory mediators after total hip arthroplasty in patients with disabling osteoarthritis. Pain Practice, 2021, , .	0.9	5
432	Insights on Genetic and Environmental Factors in Parkinsonâ€™s Disease from a Regional Swedish Case-Control Cohort. Journal of Parkinson's Disease, 2022, 12, 153-171.	1.5	5

#	Article	IF	Citations
433	Midsagittal corpus callosal thickness and cognitive impairment in Parkinson's disease. European Journal of Neuroscience, 2022, 55, 1859-1872.	1.2	5
434	Graft Survival. Journal of Neurosurgery, 1999, 90, 804-6.	0.9	4
435	Evaluation of GeneMapperÂ®ID-X Mixture Analysis tool. Forensic Science International: Genetics Supplement Series, 2011, 3, e11-e12.	0.1	4
436	Increased CSF biomarkers of angiogenesis in Parkinson disease. Neurology, 2016, 86, 1747-1748.	1.5	4
437	Cerebrospinal fluid biomarkers for the diagnosis and prognosis of Parkinsonâ€™s disease: protocol for a systematic review and individual participant data meta-analysis. BMJ Open, 2017, 7, e018177.	0.8	4
438	SCRT1 is a novel beta cell transcription factor with insulin regulatory properties. Molecular and Cellular Endocrinology, 2021, 521, 111107.	1.6	4
439	Reporting frequency of radiology findings increases after introducing visual rating scales in the primary care diagnostic work up of subjective and mild cognitive impairment. European Radiology, 2021, 31, 666-673.	2.3	4
440	Management of Alzheimer's disease takes a leap forward. Lancet Neurology, The, 2021, 20, 586-587.	4.9	4
441	Astrocytic function is associated with both amyloid-Î² and tau pathology in non-dementedAPOE Ïµ4carriers. Brain Communications, 2022, 4, .	1.5	4
442	Brain activity and Alzheimerâ€™s disease: a complex relationship. Brain, 2016, 139, 2109-2110.	3.7	3
443	[ICâ€02â€“05]: ABNORMAL STRUCTURAL BRAIN CONNECTOME IN INDIVIDUALS WITH PRECLINICAL ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P7.	0.4	3
444	Extreme sleep pattern in Lewy body dementia: a hypothalamic matter?. BMJ Case Reports, 2019, 12, e228177.	0.2	3
445	Cerebrospinal Fluid Biomarker Levels as Markers for Nursing Home Placement and Survival Time in Alzheimerâ€™s Disease. Current Alzheimer Research, 2021, 18, 573-584.	0.7	3
446	Towards a universal cortical tau sampling mask. Alzheimer's and Dementia, 2021, 17, .	0.4	3
447	Evaluation of plasma AÎ²40 and AÎ²42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiology of Aging, 2010, 31, 541.	1.5	2
448	Reply: Heterozygous PINK1 p.G411S in rapid eye movement sleep behaviour disorder. Brain, 2017, 140, e33-e33.	3.7	2
449	Systematic Development of Small Molecules to Inhibit Specific Microscopic Steps of Amyloid-Beta42 Aggregation in Alzheimer's Disease. Biophysical Journal, 2018, 114, 225a.	0.2	2
450	Forensic genetics: the basics. , 2020, , 1-53.		2

#	Article	IF	Citations
451	Modeling patientâ€specific tau spreading patterns in Alzheimerâ€™s disease: Towards precision medicine. Alzheimer's and Dementia, 2020, 16, e040587.	0.4	2
452	The accumulation rate of tau aggregates is higher in females and younger individuals. Alzheimer's and Dementia, 2020, 16, e043876.	0.4	2
453	Prediction of future Alzheimerâ€™s disease dementia using plasma phosphoâ€tau combined with other accessible measures. Alzheimer's and Dementia, 2021, 17, .	0.4	2
454	Automatic data processing of reference DNA-profiles from FTA and non-FTA samples. Forensic Science International: Genetics Supplement Series, 2008, 1, 29-31.	0.1	1
455	Proteinase K challenged by a novel protease. Forensic Science International: Genetics Supplement Series, 2008, 1, 32-34.	0.1	1
456	Free open source software for internal validation of forensic STR typing kits. Forensic Science International: Genetics Supplement Series, 2013, 4, e300-e301.	0.1	1
457	Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimerâ€™s disease. BMC Neurology, 2015, 15, 8.	0.8	1
458	[P4â€“152]: DIFFERENCES IN ANALYTICAL SELECTIVITY OF Î²â€AMYLOID (1â€“42) IMMUNOASSAYS EXPLAIN DISCORDANT RESULTS IN STUDY COMPARISONS. Alzheimer's and Dementia, 2017, 13, P1316.	0.4	1
459	P3â€267: ANALYSIS OF CEREBROSPINAL FLUID (CSF) BIOMARKERS TO PREDICT RISK OF CLINICAL DECLINE AND PROGRESSION TO DEMENTIA IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT AND MILD COGNITIVE SYMPTOMS. Alzheimer's and Dementia, 2018, 14, P1178.	0.4	1
460	Genetic characterization of amyloid-Î² and tau network spread. Nature Medicine, 2018, 24, 1790-1792.	15.2	1
461	P4â€540: CSF PTAUâ€217 PERFORMS BETTER THAN PTAUâ€181 IN DETECTING ABNORMAL RETENTION OF ¹⁸FâFLORTAUCIPIR AND DISCRIMINATING ALZHEIMER'S DISEASE FROM OTHER NEURODEGENERATIVE DISORDERS. Alzheimer's and Dementia, 2019, 15, P1523.	0.4	1
462	Empirical characterization of DNA profiles. , 2020, , 55-88.		1
463	Inter-modality assessment of medial temporal lobe atrophy in a non-demented population: application of a visual rating scale template across radiologists with varying clinical experience. European Radiology, 2021, , 1.	2.3	1
464	Connecting Cohorts to Diminish Alzheimerâ€™s Disease (CONCORD-AD): A Report of an International Research Collaboration Network. Journal of Alzheimer's Disease, 2021, , 1-15.	1.2	1
465	Plasma glial fibrillary acidic protein is an early and specific marker of amyloidâ€Î² pathology in Alzheimerâ€™s disease. Alzheimer's and Dementia, 2021, 17, .	0.4	1
466	Associations between longitudinal neuropsychiatric symptoms and betaâ€amyloid, tau, neurodegeneration, and cognitive decline. Alzheimer's and Dementia, 2021, 17, .	0.4	1
467	P4-023: INCREASED LEVELS OF ANGIOGENIC FACTORS IN THE CEREBROSPINAL FLUID ARE ASSOCIATED WITH COGNITIVE IMPAIRMENT IN PARKINSOÅƒS DISEASE. , 2014, 10, P791-P791.		0
468	P2-101: EVALUATION OF THE PRESYNAPTIC PROTEIN SNAP-25 AS A NOVEL CEREBROSPINAL FLUID MARKER FOR SYNAPTIC PATHOLOGY IN ALZHEIMER'S DISEASE. , 2014, 10, P508-P508.		0

#	Article	IF	Citations
469	P4â€339: Earlyâ€and Lateâ€Onset Alzheimerâ€™S Disease are Associated with Distinct Regional TAU Pathology as Examined with [18]Fâ€AVâ€1451 TAU Positron Emission Tomography. Alzheimer's and Dementia, 2016, 12, P1164.	0.4	0
470	Decreased ratio between Î²-amyloid 42 (AÎ²42) and AÎ²40 in cerebral spinal fluid is a better predictor of structural brain changes than AÎ²42 alone in cognitively normal elderly people. Neurobiology of Aging, 2016, 39, S17.	1.5	0
471	[ICâ€Pâ€123]: ATROPHY OF THE POSTERIOR SUBICULUM IS ASSOCIATED WITH MEMORY IMPAIRMENT, TAU AND AÎ² PATHOLOGY IN NONâ€DEMENTED INDIVIDUALS. Alzheimer's and Dementia, 2017, 13, P94.	0.4	0
472	[P3â€“132]: CSF BIOMARKERS OF NEUROINFLAMMATION ARE ELEVATED IN PRECLINICAL AND PRODROMAL AD AND CORRELATE WITH TAU PATHOLOGY. Alzheimer's and Dementia, 2017, 13, P985.	0.4	0
473	[P3â€“402]: PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE AND AMYLOID PATHOLOGY EXHIBIT SIGNIFICANT BRAIN ATROPHY, TAU PATHOLOGY AND MILD MEMORY DIFFICULTIES. Alzheimer's and Dementia, 2017, 13, P1117.	0.4	0
474	[P4â€“197]: EMERGING AMYLOID PATHOLOGY. Alzheimer's and Dementia, 2017, 13, P1340.	0.4	0
475	[P1â€“150]: INVESTIGATION OF THE ASSOCIATION BETWEEN GENETIC VARIATION IN IL1RAP AND ALZHEIMER'sâ€RELATED CSFâ€BIOMARKERS. Alzheimer's and Dementia, 2017, 13, P300.	0.4	0
476	[ICâ€Pâ€098]: ASSOCIATION BETWEEN CEREBROSPINAL FLUID AND PLASMA NEURODEGENERATION BIOMARKERS WITH BRAIN ATROPHY IN ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P75.	0.4	0
477	[ICâ€Pâ€199]: [18]Fâ€AVâ€1451 PET IN CLINICALLY DIAGNOSED CORTICOBASAL DEGENERATION. Alzheimer's and Dementia, 2017, 13, P146.	0.4	0
478	[P2â€“246]: NOVEL CSF FRAGMENTS OF TAU: CANDIDATE BIOMARKERS OF ALZHEIMER's DISEASE AND TAUOPATHIES. Alzheimer's and Dementia, 2017, 13, P706.	0.4	0
479	1947Biomarkers of microvascular endothelial dysfunction may predict dementia. European Heart Journal, 2017, 38, .	1.0	0
480	P4237N-terminal prosomatostatin predicts vascular dementia but not alzheimers disease. European Heart Journal, 2017, 38, .	1.0	0
481	P3â€413: HETEROGENEOUS TAUâ€PET SIGNAL IN THE HIPPOCAMPUS HELPS RESOLVE DISCREPANCIES BETWEEN IMAGING AND PATHOLOGY. Alzheimer's and Dementia, 2018, 14, P1263.	0.4	0
482	ICâ€Pâ€224: HETEROGENEOUS TAUâ€PET SIGNAL IN THE HIPPOCAMPUS HELPS RESOLVE DISCREPANCIES BETWEEN IMAGING AND PATHOLOGY. Alzheimer's and Dementia, 2018, 14, P182.	0.4	0
483	O2â€09â€02: A UNIFIED PREâ€ANALYTICAL PROTOCOL FOR HANDLING OF CSF SAMPLES BEFORE ANALYSES OF AD BIOMARKER LEVELS. Alzheimer's and Dementia, 2018, 14, P641.	0.4	0
484	ICâ€Pâ€036: POSITIVE ASSOCIATION BETWEEN THE EARLIEST STAGE OF AMYLOID UPTAKE AND FUNCTIONAL CONNECTIVITY IN NONâ€DEMENTED ELDERLY SUBJECTS. Alzheimer's and Dementia, 2018, 14, P39.	0.4	0
485	Primary fatty amides are potential plasma biomarkers for AD. Nature Reviews Neurology, 2019, 15, 498-499.	4.9	0
486	P4â€531: CEREBROSPINAL FLUID APOLIPOPROTEIN E ISOFORM CONCENTRATIONS IN RELATION TO Î²â€AMYLOID POSITIVITY. Alzheimer's and Dementia, 2019, 15, P1517.	0.4	0

#	Article	IF	Citations
487	P1588Beta-blocker therapy and risk of dementia: a population-based prospective study. European Heart Journal, 2019, 40, .	1.0	0
488	P4â€473: A NOVEL MASS SPECTROMETRIC METHOD FOR THE ABSOLUTE QUANTIFICATION OF SIX AÎ² PEPTIDES IN HUMAN CEREBROSPINAL FLUID. Alzheimer's and Dementia, 2019, 15, P1492.	0.4	0
489	DTâ€01â€04: DIAGNOSTIC PERFORMANCE OF [¹⁸F]RO948 PET IN THE SEPARATION OF ALZHEIMER'S DISEASE FROM OTHER NEURODEGENERATIVE DISORDERS: FINDINGS FROM THE BIOFINDERâ€2 STUDY. Alzheimer's and Dementia, 2019, 15, P1485.	0.4	0
490	Allele drop-out and the stochastic threshold. , 2020, , 89-110.		0
491	Low-template DNA. , 2020, , 111-128.		0
492	A qualitative (semi-continuous) model: LRmix Studio. , 2020, , 153-179.		0
493	Investigative forensic genetics: SmartRank, CaseSolver and DNAmatch2. , 2020, , 339-383.		0
494	Improved performance of Elecsys CSF Abeta measurement achieved using the simple, unified routineâ€use protocol for CSF collection. Alzheimer's and Dementia, 2020, 16, e047394.	0.4	0
495	Cadmium and lead exposure and risk of dementia in a Swedish population-based cohort: The MalmÃ¶ Diet and Cancer Study. ISEE Conference Abstracts, 2021, 2021, .	0.0	0
496	Genome editing (CRISPR-Cas9) to identify and characterise functional variants determining metformin response. , 2018, 13, .		0
497	Ability of tauâ€PET, phosphoâ€tau217, NfL and cortical thickness to predict shortâ€term cognitive decline in early symptomatic Alzheimerâ€™s disease. Alzheimer's and Dementia, 2021, 17, .	0.4	0
498	Unravelling drivers of ageâ€and betaâ€amyloidâ€related neurodegeneration in medial temporal lobe atrophy in cognitively normal older adults. Alzheimer's and Dementia, 2021, 17, .	0.4	0
499	Establishment of updated biomarker cutâ€off values for the secondâ€generation Elecsys Î²â€amyloid(1â€“42), pTau and tTau CSF immunoassays. Alzheimer's and Dementia, 2021, 17, .	0.4	0
500	Soluble Pâ€tau217 reflects both amyloid and tau pathology in the human brain and mediates the association of amyloid with neocortical tau. Alzheimer's and Dementia, 2021, 17, .	0.4	0
501	Inflammatory, degeneration and neuritic growth biomarkers predict cognitive decline and dementia in Parkinsonâ€™s disease. Alzheimer's and Dementia, 2021, 17, .	0.4	0
502	Biomarker driven enrichment strategies for tau pathology in AD clinical trials. Alzheimer's and Dementia, 2021, 17, .	0.4	0
503	Impact of reduced injected dose on the quantification of [¹⁸ F]RO948 and [¹⁸ F]Flortaucipir PET for in vivo tau pathology. Alzheimer's and Dementia, 2021, 17, .	0.4	0
504	Tau and synaptic biomarkers but not amyloidâ€Î² are associated with cerebral perfusion in the Alzheimerâ€™s disease spectrum. Alzheimer's and Dementia, 2021, 17, .	0.4	0

#	Article	IF	Citations
505	Tau deposition is associated with grey matter network breakdown across different stages of the Alzheimerâ€™s disease continuum. Alzheimer's and Dementia, 2021, 17, .	0.4	0
506	Plasma biomarkers predict longitudinal amyloid accumulation, tau burden, brain atrophy and cognitive decline in early Alzheimerâ€™s disease. Alzheimer's and Dementia, 2021, 17, .	0.4	0
507	Lower cognitive resilience against brain atrophy in cognitively unimpaired elderly is partly explained by Alzheimer's disease pathology. Alzheimer's and Dementia, 2021, 17, .	0.4	0
508	Comparing the clinical utility and diagnostic performance of cerebrospinal fluid Pâ€tau181, Pâ€tau217 and Pâ€tau231 assays. Alzheimer's and Dementia, 2021, 17, .	0.4	0
509	Amyloidâ€Î² accumulation is independently related to executive function in cognitively unimpaired adults. Alzheimer's and Dementia, 2021, 17, .	0.4	0
510	Associations between cerebrospinal fluid markers of neuroinflammation and longitudinal measurements of white matter lesions. Alzheimer's and Dementia, 2021, 17, .	0.4	0
511	The association between diet in midâ€life and dementia incidence over a 20â€year period. Alzheimer's and Dementia, 2021, 17, .	0.4	0
512	Potential drivers of ageâ€and betaâ€amyloidâ€related neurodegeneration in early and late Alzheimerâ€™s Disease regions in cognitively normal older adults. Alzheimer's and Dementia, 2021, 17, .	0.4	0
513	[¹⁸ F]RO948 tau PET in bvFTD due to C9orf72 and GRN mutations. Alzheimer's and Dementia, 2021, 17, .	0.4	0
514	Sex differences in blood-based biomarkers in individuals with autosomal dominant Alzheimer's disease.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e055011.	0.4	0